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1 Introduction
The term cachexia embraces a complex metabolic syndrome
characterized by loss of body weight that may develop as a
consequence of loss of muscle mass with or without loss of
fat mass; bone mineral density may be affected as well [1].
Over the last 10 years, the Cachexia Conference has devel-
oped a forum for researchers from the fields of cachexia and
wasting disorders. It is unique in several ways as it provides
a platform for both clinicians and basic researchers to meet
and discuss pathways and potential therapeutic targets as
well as recent evidence from clinical trials. The 6th Cachexia
Conference was held in Milan, Italy, from 8 to 10 December
2012 with over 400 participants from more than 25 countries
attending [2].
Cachexia remains underdiagnosed and undertreated, even
though it is prevalent among many patients presenting with
cancer, chronic heart failure, chronic obstructive pulmonary
disease, human immunodeficiency virus infection or chronic
kidney disease. Creating awareness for cachexia is one of
the major aims of the Cachexia Conference as well as the
improvement of patients' morbidity, mortality and quality of
life. A more thorough understanding of the underlying
mechanisms and pathophysiology may help in achieving
these aims. The identification of such mechanisms may help
to identify therapeutic targets and potential biomarkers that
help to detect loss of tissue as early as possible. Many
excellent animal and clinical studies were presented at the
meeting in Milan, and the following overview seeks to
highlight some major research areas in the field of cachexia
and body wasting.
2 Muscle mitochondrial dysfunction
A number of elegant models were presented in order to
improve our understanding of pathways involved in the
wasting process. Muscle wasting has received increasing
research efforts in recent years. Thus, one of the hot topics
of the meeting was the investigation of muscle proteolytic
pathways. Slimani et al. from Didier Attaix's group (Clermont
University, Clermont-Ferrand, France) used a rat model of
immobilisation-induced muscle atrophy to examine underly-
ing pathomechanisms. They demonstrated that proteolysis via
the ubiquitin proteasome system (UPS) and mitochondrium-
associated apoptosis are involved in muscle remodelling
during early recovery in immobilised muscle [3]. In addition,
these authors demonstrated that the muscle-specific E3
ubiquitin ligase muscle RING-finger protein 1 (MuRF1) is
up-regulated during catabolic conditions and that it is involved
in the polyubiquitinylation of components of the thick
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filament. Interestingly, actin is being degraded in a specific
pattern despite myosin degradation. Thick actin filaments
degrade earlier than thin actin filaments. Unfortunately, the
question of whether the order of actin filament degradation is
clinically relevant with regards to the reversibility of the
muscle wasting process remains unanswered. Importantly,
the abundant contractile protein actin is a target of the UPS
in skeletal muscle both in vitro and in vivo, further supporting
the need for new strategies to block specifically the activation
of this pathway in muscle wasting conditions [4].
Several investigators studied mitochondrial dysfunction
and its role in muscle wasting. The current conclusion of these
reports is that mitochondrial dysfunction seems to be the
principal pathway in sarcopenia, i.e. age-related loss of muscle
mass [5]. It may be important to differentiate between muscle
wasting as part of ‘healthy ageing’ in contrast to muscle loss in
chronic disease, as the involved processes could be funda-
mentally different [6]. At the meeting, special emphasis was
put on possible steps involved in sarcopenia during the ageing
process. Chikwendu Ibebunjo et al. (Novartis Institutes for
Biomedical Research, Cambridge, Massachusetts, USA) sub-
jectedmuscle samples tomicroarray and proteomic analysis in
a rat sarcopenia model. The phenotypic, genomic and proteo-
mic features of sarcopenia in these rats were similar to those of
human sarcopenia and suggest that the animals may provide a
suitable model for mechanistic studies of sarcopenia. Indeed,
whilst pathways of mitochondrial energy metabolism (tricar-
boxylic acid cycle and oxidative phosphorylation) were sig-
nificantly down-regulated in sarcopenic rats, genes associated
with the neuromuscular junctionwere up-regulated [7]. There-
fore, intervention strategies that counteract these dysregula-
tions may be beneficial for prevention or treatment of
sarcopenia. In line with this observation is the work of the
group by Siegfried Labeit (Medical Faculty of Mannheim,
Mannheim, Germany) that used MuRF1-knockout mice to
analyse the role of E3 ligase MuRF1 in sarcopenia. Gene
inactivation of MuRF1 resulted in potent protection
from muscle atrophy induced by stimuli such as dener-
vation, hindlimb suspension or injection of tumour ne-
crosis factor-α (TNFα) [8]. They noted that fast fibre
types were preferentially protected. Furthermore, in line
with systemic regulatory effects of MuRF1 in muscle
atrophy, metabolic effects on lipid and glucose oxidation and
circulating amino acid levels could be detected. Therefore,
future studies are warranted to identify additional pathways
that are regulated by MuRF1.
3 Cytokines
The activation of pro-inflammatory cytokines and a dysba-
lance between pro- and anti-inflammatory mediators play
important roles in the pathophysiology of cachexia and
muscle wasting in chronic illness. Cytokines are currently
thought of as among the principal catabolic players in skeletal
muscle.
Pedro L. Martinez-Hermandez (Hospital University
La Paz, Madrid, Spain) collected data from 21 cancer
patients and 8 healthy controls. The authors measured
interleukin-15 (IL-15) at weeks 4 and 8, respectively,
because IL-15 might be directly associated with changes
in body weight [9]. Baseline levels of IL-15 were similar
between cancer patients and controls. Whilst cancer patients
who gained weight (n05) had an increase in IL-15 serum
levels, this was not the case in patients who lost weight
(n013).
Pro-inflammatory cytokines such as IL-6 have likewise
seen increasing research efforts over the last several years.
The group of James A. Carson (University of South Caro-
lina, Columbia, South Carolina, USA) used the ApcMin/
mouse that develops severe cachexia and reduced muscle
oxidative capacity, to study a possible role of IL-6 receptor
antagonism and exercise in restoring mitochondrial function
in cancer cachexia [10]. They found that whilst loss of
muscle oxidative capacity occurs late in the course of ca-
chexia development, decreased expression of regulators of
mitochondrial biogenesis and dynamics occur rather early.
These data demonstrate clearly that blockade of IL-6 dependent
signalling can reverse deteriorated mitochondrial function in
this model of severe cachexia.
Andrea Bonetto (Thomas Jefferson University, Phila-
delphia, USA) and his group concentrated their research
on the signalling of IL-6 and of signal transducer and
activators of transcription 3 (STAT3), which is known to
induce muscle wasting in cancer cachexia [11]. Since
the suppressor of cytokine signalling 3 (SOCS3) is one
of the inhibitors of the IL-6/STAT3 pathway, SOCS3
over-expression in C2C12 myotubes by means of in
vitro adenoviral infection was used to counteract this
pathway. Indeed, C2C12 myotubes that over-express
SOCS3 proved resistant to IL-6-induced wasting. Fur-
thermore, transgenic mice (MLC-SOCS3 C57BL/6)
served to isolate the effects of SOCS3 on skeletal mus-
cle. Interestingly, muscle weight was increased in female
MLC-SOCS3 transgenic animals only, suggesting a gender-
specific function of SOCS3. In cancer cells, over-active
receptor and non-receptor-bound tyrosine kinases cause per-
sistent STAT3 phosphorylation (p-STAT3) and hence, STAT3
activation. Mice bearing the colon-26 adenocarcinoma (C26)
exhibit severe muscle wasting that was associated with
increased levels of p-STAT3. The researchers demonstrated
elegantly that localized over-expression of SOCS3 in the
tibialis muscle inhibits STAT3 activation and thus prevents
muscle wasting in C26 mice. Therefore, SOCS3 seems to be a
possible therapeutic target in cachexia induced by tumours
with high IL-6/STAT3 signalling [11].
46 J Cachexia Sarcopenia Muscle (2012) 3:45–50
4 Therapeutic interventions targeting deleterious
cytokine signalling
A very impressive example of the clinical importance of
deleterious IL-6 signalling in cancer cachexia was reported
by Miho Murakami and colleagues (Wakayama Medical
University, Ibaraki, Japan). They used tocilizumab (TCZ),
a humanized anti-human IL-6 receptor antibody, in a patient
with advanced malignant mesothelioma [12]. In their case
report, a 76-year old man with recurrent malignant meso-
thelioma of the pleura was treated with tocilizumab at a dose
of 8 mg/kg of body weight every other week. The tumour
had been refractory to standard polychemotherapy and radi-
ation, and therefore treatment with tocilizumab was com-
menced. The drug lowered subfebrile temperatures and
normalized IL-6-dependent plasma markers of cachexia like
C-reactive protein, vascular endothelial growth factor and
ghrelin within 2 weeks. Whilst tocilizumab increased pre-
albumin and retinol binding protein, leptin levels were not
changed. The general status of the patient was considerably
improved as documented by the Eastern Cooperative
Oncology Group performance status (ECOG PS scale).
Since the patient suffered from radiation pneumonitis
caused by previous treatment, tocilizumab had eventually
been discontinued. Unfortunately, tumour growth increased
rapidly thereafter [12]. Thus, further studies are warranted to
elucidate whether blockade of IL-6 action in patients with
malignant mesothelioma can improve outcomes and possi-
bly the course of cancer cachexia.
Vasilis Paspaliaris (Itis Pharmaceuticals Pty Ltd.,
Melbourne, Australia) presented data from a phase I/II study
of IP-1510, a novel interleukin-1 (IL-1) receptor antagonist
that was used in 26 patients with cachexia caused by
advanced gynaecological cancer. They measured stabiliza-
tion and increases in body weight in 17 patients who were
treated with IP-1510 at a dose of 1 mg twice daily over
28 days [13]. IP-1510 was well tolerated and safe in patients
with advanced cancer. The interpretation of the current data
is limited because the study was neither randomised nor
blinded or controlled. Large-scale clinical studies are needed
to prove whether neutralization of deleterious cytokines or
direct receptor antagonism is an effective therapeutic
approach to improve patient outcomes or to reverse muscle
loss in cachexia.
5 Therapeutic approaches to counteract
immobilisation-induced atrophy
Different studies concentrated on the mechanisms of muscle
wasting induced by immobilisation. A study by L. Larsson
(Department of Clinical Neurophysiology, Uppsala, Sweden)
aimed to improve the understanding of mechanisms
underlying the muscle type-specific differences in critically
ill patients with acute quadriplegic myopathy. Using a porcine
model, they found an up-regulation of UPS activity after
5 days of immobilisation. In addition, up-regulation of heat
shock molecular chaperones as well as a concomitant down-
regulation of sarcomeric proteins such as MURF2 and growth
factors like insulin-like growth factor-1 (IGF-1) or IGF-2 were
reported [14].
Several elegant studies either derived from animal data or
from cell lines were presented with regards to the role of
microRNAs (miRNA) in skeletal muscle wasting during
cancer cachexia. Each miRNA has multiple target genes
(200–500) and thus represents an attractive tool to study
putative genes involved in the development of cancer
cachexia. Nathan A. Stephen (University of Edinburgh,
Edinburgh, UK) showed that cancer cachexia is associated
with significantly increased expression of skeletal muscle
miR-29b, miR-143, miR-100, miR-768-3p and miR-193b
whereas miR-208a is decreased. Quantitative polymerase
chain reaction (PCR) validation of these differentially
expressed miRNAs indicated that only miR-29b correlated
with weight loss (r00.5, p00.03) [15, 16]. Therefore, selected
miRNAs may represent potential biomarkers for early detec-
tion of muscle wasting and targets for future interventions.
Another approach involves expression patterns of mRNA
in skeletal muscle. Christopher M. Adams (University of
Iowa, Iowa City, Iowa, USA) showed mRNA expression
signatures of human skeletal muscle atrophy to identify a
small molecular inhibitor of muscle atrophy. Ursolic acid, a
naturally triterpene acid present in the fatty layer of several
fruits and herbs, was used to demonstrate reduction in
muscle athrophy. For this purpose, the authors used three
distinct mouse models: fasting, denervation and immobili-
sation. They identified 63 mRNAs in human and mouse
muscle that are regulated by fasting in human and mouse
muscle, and 29 mRNAs were regulated by both fasting and
spinal cord injury (i.e. denervation). Their data showed that
ursolic acid reduced atrophy and stimulated hypertrophy by
enhancing skeletal muscle insulin/IGF-1 signalling and
inhibiting atrophy-associated mRNA expression. Thus,
the authors concluded that ursolic acid and the research
on mRNAs may help to prevent and treat muscle atrophy
[17].
Jan Vrijbloed (Neurotune AG, Schlieren, Switzerland)
presented a new animal model of sarcopenia, the so-called
SARCO mouse, a transgenic mouse over-expressing the
human enzyme neurotrypsin. This enzyme produces
c-terminal agrin fragment from the peptide agrin, a synapti-
cally located key player during initial formation and main-
tenance of neuromuscular junctions. Levels of c-terminal
agrin fragment are significantly elevated in a large number
of patients with sarcopenia. The SARCO mouse may there-
fore offer novel starting points for research of pathogenic
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mechanisms in sarcopenia that could be used for pharma-
ceutical treatments [18].
6 MT-102, an anabolic/catabolic transforming agent
Another intriguing approach to the treatment of muscle
wasting was presented by Mareike Pötsch (Charité Medical
School, Berlin, Germany) who showed data from an animal
model using the new anabolic/catabolic transforming agent
MT-102 in order to reverse muscle wasting in cancer ca-
chexia in the rat. Rats that were inoculated intra-peritoneally
with 108 Yoshida AH-130 hepatoma cells and were then
treated with MT-102 at a dose of 3.0 mg/kg/day resulted in a
gain of lean mass and body weight. On day 11, left ventricular
ejection fraction (p<0.01), fractional shortening (p<0.05),
and stroke volume (p<0.01) were significantly improved by
MT-102 [19]. The ACT-ONE trial, a multicentre, randomised,
double-blind, placebo-controlled, dose-finding study of the
anabolic/catabolic transforming agent MT-102 that has recent-
ly commenced recruitment of subjects with cachexia related to
stages III and IV non-small cell lung cancer or colorectal
cancer needs to confirm whether these animal data can be
translated into humans [20].
7 Clinical studies/growth hormone
Several factors have complicated the development of effec-
tive therapies for cachexia particularly the many different
pathways involved in the development of the disease. The
focus of many therapies includes nutritional interventions.
There has been little consensus on the primary end point for
clinical trials, which has hampered assessment of the efficacy
of treatments. Results of randomised, double-blind, placebo-
controlled adequately powered clinical trials in the field of
cachexia are eagerly awaited.
A promising approach was presented by John Friend
(Helsinn Therapetuics Inc, Bridgewater, New Jersey, USA)
who provided insight into the design of a randomised,
double-blind, placebo-controlled, multicenter phase III
study to evaluate the safety and efficacy of anamorelin in
patients with non-small-cell lung carcinoma (NSCLC). Ana-
morelin is an orally active ghrelin receptor agonist. Ghrelin
is a physiological ligand of the growth hormone secreta-
gogue receptor that stimulates food intake. Anamorelin as a
potential ghrelin-analog seems to be a therapeutic agent with
possible effects during all stages of cachexia. Study results are
estimated to be presented at the 7th Cachexia Conference in
Kobe in December 2013.
Plasma ghrelin levels are elevated in cachectic patients
with chronic heart failure possibly through a compensatory
mechanism to a catabolic/anabolic imbalance [21, 22].
Exogenously administered ghrelin has been shown to improve
left ventricular dysfunction and to attenuate the development
of cardiac cachexia in rats with heart failure. Thus, supple-
mentation of ghrelin could be a therapeutic approach in the
treatment of chronic heart failure [23, 24]. A naturally occur-
ring splice variant of ghrelin (Dln-101) with 57% homology to
ghrelin was presented. Liat Mintz (DiaLean Ltd., East
Brunswick, New Jersey, USA) conducted extensive pre-
clinical studies showing that Dln101 acts similarly to ghrelin
in increasing food intake, promoting weight gain and increas-
ing growth hormone release. In addition, Dln-101 suppresses
inflammation and has beneficial effects on the metabolic
profile in terms in reducing cholesterol and glucose levels.
Thus, Dln-101 has received approval to start phase I clinical
trials [25].
8 Erythropoietin
Yulia Elkina (Charite Medical School, Berlin, Germany)
and colleagues showed the tissue-protective effect of the
non-hematopoietic erythropoietin analogues ARA284 and
ARA286 in the treatment of cancer cachexia in a rat cancer
cachexia model. ARA284 and ARA286 in high concentra-
tions (5,000 units/kg/day) were shown to be effective in
reducing tissue wasting in rat cancer cachexia model. These
compounds should be seen as prospective drugs for human
cancer cachexia [26].
9 Selective androgen receptor modulators
Selective androgen receptor modulators (SARMs) belong to
a relatively new class of therapeutics that possesses anabolic
properties. SARMs are currently in the early stages of de-
velopment [27]. A double-blind, placebo-controlled phase II
clinical trial with GTx-024 (enobosarm) in 120 healthy
elderly men and women showed a dose-dependent (3 mg
of enobosarm) improvement in total lean body mass and
physical function [28]. Shontelle Dodson (GTx Inc., Mem-
phis, USA) and colleagues analysed enobosarm that was
used in the treatment of 159 patients with NSCLC with
muscle wasting [29]. The group that received enobosarm
showed positive effects on quality of life. Additionally, they
found a benefit with regards to stair climbing power, a readily
available measure of exercise capacity, frequently used by
geriatricians. Moreover, stair climbing power benefit (defined
as 10% improvement) correlated with quality of life (measured
with functional assessment of cancer therapy). According to
that, enobosarm had an impact on physical function, quality of
life, and it had the ability to overcome the negative prognostic
effect of >8% weight loss on overall survival [30]. Eric Vajda
(Ligand Pharmaceuticals, La jolla, California, USA) presented
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data from another novel SARM termed LGD-4033 that was
used in healthy young men. In this randomised, placebo-
controlled study, the dose of 0.1, 0.3 or 1 mg LGD-4033 daily
was studied over a time of 21 days. This treatment phase was
followed by a 5-week observation period. The study showed a
dose-dependent increase in lean body mass (about 1.2 kg) in
patients who were treated with 1 mg LGD-4033 [31]. The
investigators are planning a phase II study to evaluate LGD-
4033 in conditions such as muscle wasting associated with
cancer and acute illness. The mechanism by which steroidal
and non-steroidal SARMs produce selective tissue-specific
anabolic responses has not been fully elucidated. However,
further studies are necessary to evaluate the mechanism and
long-term effect of SARMs in patients with cachexia.
10 Conclusions
Several pathways have been shown to play important roles in
muscle wasting in the muscle wasting process: actin as a target
of UPS, MuRF-regulated pathways or IL-15 that may be
directly associated with loss of body weight. Potential bio-
markers for cachexia are currently under investigation. There
is further need for attractive biomarkers as therapeutic targets
in the context of cachexia. The outcome criteria of drug
studies in cancer cachexia need to focus not only on mortality,
but also on symptoms and quality of life rather than simply on
nutritional end-points, since the survival of cachectic cancer
patients is usually limited to weeks or months due to the
incurable nature of the underlying malignancy. In summary,
cachexia and sarcopenia need more attention in clinical work
and research and prospective clinical randomised, double
blinded, placebo-controlled studies are needed. Prospective
large-scale studies are warranted, such as the Studies Inves-
tigating Co-morbidities Aggravating Heart Failure
(SICA-HF), a multicenter pathophysiological observa-
tional study which is particular looking at cachexia and
obesity prevalence in chronic heart failure [32]. The
results thereof will be presented in Kobe in 2013.
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